Gallbladder and Biliary Disease Journal Articles

• Risk Control and Treatment in Patients With NAFLD and T2D A better understanding of the trends in risk factor control and medication use in this population could help improve the management of these patients.
  Alimentary Pharmacology & Therapeutics, June 06, 2023
• Obesity and Alcohol Impacts Genetic Risk for Liver Disease A new study shows that abdominal obesity and alcohol use amplifies the impact of genetic risk for developing liver disease, highlighting the importance of lifestyle modification.
  Liver International, June 02, 2023
• Drug-induced Liver Injury Due to Tofacitinib This report details the clinical manifestations of tofacitinib-associated drug-induced liver injury in a patient receiving the Janus kinase inhibitor daily for five months.
  Journal of Medical Case Reports, June 02, 2023
• Overweight Years and Risk of NAFLD, Fibrosis and Cirrhosis A new study looks at the potential impact of a longer duration of excess body weight on the polygenic risk of NAFLD and significant fibrosis.
  Alimentary Pharmacology & Therapeutics, June 01, 2023
• Non-Invasive Testing for Predicting NASH and Fibrosis This paper proposes an algorithm incorporating non-invasive testing to identify at-risk NASH patients and assess the level of fibrosis.
  Liver International, May 26, 2023
• Vitamin E-induced Coagulopathy in a Young Patient This case highlights the risk of vitamin E-related coagulopathy due to inhibition of vitamin K-dependent factors, even at marginally increased levels of serum vitamin E.
  Journal of Medical Case Reports, May 26, 2023
• Strategies to Increase PCP Capacity for Hepatitis C Care The authors report on the development and implementation of a multi-faceted program utilizing both hub-and-spoke and telementoring strategies to support PCP education and training in HCV care.
  Journal of Viral Hepatitis, May 22, 2023
• Gut Microbiota and Cardiovascular Drugs This article explores the the complex relationship between the gut microbiome and various common cardiovascular drugs. How might a patient's microbiome influence drug pharmacokinetics?
  U.S. Pharmacist, May 17, 2023
• Treating Borderline Resectable Pancreatic Cancer This article describes a multidisciplinary approach to the staging and treatment of borderline resectable pancreatic adenocarcinoma.
  Chinese Clinical Oncology, May 16, 2023
• Non-invasive Fibrosis Markers in Chronic Hepatitis Delta This study evaluated the performance of eight serum fibrosis markers to non-invasively assess liver fibrosis in chronic hepatitis D. Can any replace transient elastography?
  Journal of Viral Hepatitis, May 15, 2023
• Mifepristone DILI in a Patient With Cushing Syndrome This report of a patient with Cushing syndrome with mifepristone induced liver injury provides insight to the pathophysiology of liver injury in mifepristone and anabolic steroids.
  Journal of Medical Case Reports, May 12, 2023
• Higher Mortality Among Lean Patients With NAFLD Despite a lower incidence of cirrhosis and diabetes mellitus, and similar incidence of cancer and cardiovascular disease, this study revealed a higher mortality rate among lean patients with NAFLD.
  Alimentary Pharmacology & Therapeutics, May 11, 2023
• The Need for Efficient, Patient-oriented NASH Drug Development What are the advantages of platform trials in drug development for NASH? This review examines the current NASH clinical development landscape and considerations for trial design.
  Alimentary Pharmacology & Therapeutics, May 09, 2023
• Mortality Risk Factors Following SVR After DAAs for HCV What risk factors are associated with liver-related and non-liver-related mortality in patients with SVR following DAA treatment for hepatitis C infection?
  Journal of Viral Hepatitis, May 08, 2023
• Cardiovascular Evaluation and Management of Obese Patients This paper examines the unique clinical challenges which accompany the diagnosis and treatment of cardiovascular disease in persons who are overweight or obese.
  Journal of the American College of Cardiology, May 08, 2023
• Effectiveness of mRNA Vaccines Among Children Aged 3-5 Years Do the mRNA COVID-19 vaccines effectively provide protection against symptomatic infection among children in this age group?
  Morbidity & Mortality Weekly Report, May 05, 2023
• Lower Birthweight and NAFLD: Role of Insulin Resistance Does lower birthweight impact NAFLD risk, independent of childhood and adult adiposity? Are there potential metabolic mediators for this effect?
  Liver International, May 04, 2023
• Secondary Bile Acids Identify Mild Liver Fibrosis in NAFLD Can circulating bile acid levels be used to accurately stage liver fibrosis in NAFLD?
  Alimentary Pharmacology & Therapeutics, May 02, 2023
• Potential Benefit of Corticosteroids in DILI The administration of corticosteroids to treat severe drug-induced liver injury remains controversial, but this analysis revealed no serious adverse effects and improved outcomes.
  Alimentary Pharmacology & Therapeutics, April 27, 2023
• Functional Dyspepsia: Gastric or Duodenal Disorder or Both? This comprehensive overview of the pathophysiology of functional dyspepsia highlights recent research which implicates duodenal mucosal alterations as a contributing factor.
  Alimentary Pharmacology & Therapeutics, April 25, 2023